Literature DB >> 16220049

Role of inflammation in nonalcoholic steatohepatitis.

Steve Choi1, Anna Mae Diehl.   

Abstract

PURPOSE OF REVIEW: Products of hepatic macrophages and lymphocytes are acknowledged regulators of liver injury and repair. Recent studies have identified inflammatory modulators from sources within and outside the liver that are critical to the pathogenesis and progression of chronic liver diseases, including nonalcoholic fatty liver disease. This review will focus on these developments to clarify how inflammatory mediators from adipose tissue and the liver interact to mediate the pathogenesis of nonalcoholic fatty liver disease. RECENT
FINDINGS: Hepatic steatosis and steatohepatitis are extremely prevalent in obese individuals with the metabolic syndrome. The metabolic syndrome results from abnormal production of various adipose-derived and liver-derived factors that modulate energy substrate flux to coordinate tissue anabolism and catabolism. Individuals with the metabolic syndrome produce a relative excess of proinflammatory factors. Some factors inhibit hepatic fat disposal and promote lipid accumulation within hepatocytes. The latter induces sustained hepatic generation of proinflammatory cytokines, particularly when the hepatic innate immune system becomes Th-1 polarized. Although chronic inflammation induces production of various profibrogenic factors, progression to latter stages of nonalcoholic fatty liver disease is relatively unusual in individuals with the metabolic syndrome. This may reflect requirements for additional factors that become abundant only in individuals who have additional defects in hepatic innate immunity.
SUMMARY: Obesity and the metabolic syndrome represent chronic inflammatory states and are associated with nonalcoholic fatty liver disease. Liver injury that ensues is dictated by metabolic and immunomodulatory factors that are produced by adipose tissue and within the liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220049     DOI: 10.1097/01.mog.0000182863.96421.47

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  35 in total

Review 1.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 2.  [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis].

Authors:  J Wiegand; J Mössner; H L Tillmann
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

3.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

4.  p38 MAPK signal pathway involved in anti-inflammatory effect of Chaihu-Shugan-San and Shen-ling-bai-zhu-San on hepatocyte in non-alcoholic steatohepatitis rats.

Authors:  QinHe Yang; YongJian Xu; GaoFei Feng; ChaoFeng Hu; YuPei Zhang; ShaoBing Cheng; YanPing Wang; XiangWen Gong
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

5.  Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.

Authors:  Robin H Isaacson; Juliane I Beier; Nicholas Kh Khoo; Bruce A Freeman; Zachary Freyberg; Gavin E Arteel
Journal:  J Nutr Biochem       Date:  2020-04-08       Impact factor: 6.048

6.  Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice.

Authors:  Min Tan; Robin H Schmidt; Juliane I Beier; Walter H Watson; Hai Zhong; J Christopher States; Gavin E Arteel
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-29       Impact factor: 4.219

7.  Intrahepatic natural killer T cell populations are increased in human hepatic steatosis.

Authors:  Michael Adler; Sarah Taylor; Kamalu Okebugwu; Herman Yee; Christine Fielding; George Fielding; Michael Poles
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

8.  Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease.

Authors:  Ancha Baranova; Karen Schlauch; Hazem Elariny; Mohammed Jarrar; Chase Bennett; Clare Nugent; Shobha J Gowder; Zahra Younoszai; Rochelle Collantes; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

Review 9.  The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

10.  Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression.

Authors:  Walid E Zahran; Kholoud A Salah El-Dien; Philip G Kamel; Ahmed Shawky El-Sawaby
Journal:  Indian J Clin Biochem       Date:  2012-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.